Insights

Innovative RNA Technologies Eclipsebio's development of first-in-class RNA-based platforms and solutions such as eMERGE, eRibo Pro, and eSHAPE demonstrates a strong focus on advancing RNA therapeutics. This positions them as an ideal partner for companies seeking cutting-edge tools for vaccine development, gene therapy, and RNA profiling, creating opportunities for custom assay collaborations and integrated platform services.

Strategic Acquisitions and Portfolio Expansion Recent acquisition of Terrain Biosciences and launch of the comprehensive eVERSE dataset portfolio indicate a strategic push to enhance their RNA data offerings and AI-ready resources. These initiatives open avenues for collaboration with biopharma and biotech firms looking to leverage advanced datasets and AI-driven insights for drug discovery and therapeutic optimization.

Market Focus and Client Support Targeting early-stage basic research alongside preclinical vaccine and gene therapy evaluation sectors, Eclipsebio appeals to companies involved in innovative RNA applications. They provide end-to-end partnership models, creating sales opportunities through tailored services for R&D teams emphasizing deep molecular insights, validation, and multiomic characterization.

Funding and Revenue Potential With an estimated revenue between 10 and 25 million dollars and securing 14 million dollars in funding, Eclipsebio demonstrates strong growth potential. This financial backing presents a compelling case for partners and investors interested in high-growth biotechnology niches, particularly those focused on RNA therapeutics and genomic data solutions.

Competitive Positioning Compared to large industry players like Qiagen and Illumina, Eclipsebio’s specialized focus on RNA technologies and platform development provides a niche advantage. This specialization offers targeted opportunities for custom collaborations, platform licensing, and integration with other genomics and biotech solutions, making it attractive for partners seeking innovative, agile RNA research tools.

Eclipsebio Tech Stack

Eclipsebio uses 8 technology products and services including TrackJS, Canva, Samtools, and more. Explore Eclipsebio's tech stack below.

  • TrackJS
    Analytics
  • Canva
    Audio, Video, Graphics
  • Samtools
    Data Management
  • JSON-LD
    Javascript Frameworks
  • Yoast SEO
    Search Engines
  • Yoast SEO Premium
    Search Engines
  • HSTS
    Security
  • Twitter
    Widgets

Media & News

Eclipsebio's Email Address Formats

Eclipsebio uses at least 1 format(s):
Eclipsebio Email FormatsExamplePercentage
First.Last@eclipsebio.comJohn.Doe@eclipsebio.com
35%
First@eclipsebio.comJohn@eclipsebio.com
19%
Last@eclipsebio.comDoe@eclipsebio.com
11%
First.Last@eclipsebio.comJohn.Doe@eclipsebio.com
35%

Frequently Asked Questions

Where is Eclipsebio's headquarters located?

Minus sign iconPlus sign icon
Eclipsebio's main headquarters is located at 5770 Oberlin Drive San Diego, California 92121 United States. The company has employees across 3 continents, including North AmericaAsiaEurope.

What is Eclipsebio's official website and social media links?

Minus sign iconPlus sign icon
Eclipsebio's official website is eclipsebio.com and has social profiles on LinkedInCrunchbase.

What is Eclipsebio's SIC code NAICS code?

Minus sign iconPlus sign icon
Eclipsebio's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Eclipsebio have currently?

Minus sign iconPlus sign icon
As of February 2026, Eclipsebio has approximately 44 employees across 3 continents, including North AmericaAsiaEurope. Key team members include Head Of Scientific Platforms And Strategy: W. D.Director Of Business Development: M. D.Director Of Product Development: J. C.. Explore Eclipsebio's employee directory with LeadIQ.

What industry does Eclipsebio belong to?

Minus sign iconPlus sign icon
Eclipsebio operates in the Biotechnology Research industry.

What technology does Eclipsebio use?

Minus sign iconPlus sign icon
Eclipsebio's tech stack includes TrackJSCanvaSamtoolsJSON-LDYoast SEOYoast SEO PremiumHSTSTwitter.

What is Eclipsebio's email format?

Minus sign iconPlus sign icon
Eclipsebio's email format typically follows the pattern of First.Last@eclipsebio.com. Find more Eclipsebio email formats with LeadIQ.

How much funding has Eclipsebio raised to date?

Minus sign iconPlus sign icon
As of February 2026, Eclipsebio has raised $14M in funding. The last funding round occurred on Mar 15, 2022 for $14M.

When was Eclipsebio founded?

Minus sign iconPlus sign icon
Eclipsebio was founded in 2017.

Eclipsebio

Biotechnology ResearchCalifornia, United States11-50 Employees

Eclipsebio develops first-in-class technologies, analyses, and platforms for the development of tomorrow’s RNA-based and RNA-targeting therapies. With our extensive experience in supporting early-stage basic research to evaluating preclinical vaccines and gene therapies, we provide unparalleled support for obtaining deep insights into RNA and therapeutic biology. We offer our solutions as end-to-end partnerships, including custom assay development, for biopharma and biotech companies and as a la carte services.

Our areas of support include:
- The optimization and characterization of RNA-based vaccines and therapeutics through our eMERGE platform
- Multiomic characterization of small molecule and small oligonucleotide targets
- Robust validation of on-target, and the identification of off-target, effects from small molecule and small oligonucleotide drugs
- Deep profiling of RNA for groundbreaking discoveries in academic research

Contact us today to discover how we can provide you with the insights needed for RNA success.

Section iconCompany Overview

Headquarters
5770 Oberlin Drive San Diego, California 92121 United States
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2017
Employees
11-50

Section iconFunding & Financials

  • $14M

    Eclipsebio has raised a total of $14M of funding over 2 rounds. Their latest funding round was raised on Mar 15, 2022 in the amount of $14M.

  • $10M$25M

    Eclipsebio's revenue is estimated to be in the range of $10M$25M

Section iconFunding & Financials

  • $14M

    Eclipsebio has raised a total of $14M of funding over 2 rounds. Their latest funding round was raised on Mar 15, 2022 in the amount of $14M.

  • $10M$25M

    Eclipsebio's revenue is estimated to be in the range of $10M$25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.